Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 13th Preview)
-
In vivo CRISPR Phase 3 milestone
Amsterdam UMC has reported the successful conclusion of what it describes as the world’s first Phase 3 trial of an in vivo CRISPR-based therapy, bringing CRISPR gene editing closer to broader clinical reality. The program was developed in collaboration with multiple international hospitals, with results marking a key regulatory-grade benchmark for in vivo delivery. The study’s Phase 3 completion shifts in vivo CRISPR from proof-of-concept into late-stage validation—an inflection point for assessing durability, efficacy, and safety at the scale required for potential registration. The development underscores continuing progress in overcoming delivery and dosing constraints that have historically limited in vivo genome editing. For biotech stakeholders, the trial outcome is a signal that advanced editing platforms are moving into standard clinical timelines and endpoints rather than remaining confined to early-phase studies.
-
FDA approval: adjuvant pembrolizumab–belzutifan for clear cell kidney cancer
The FDA has approved an adjuvant combination of pembrolizumab and belzutifan for high-risk clear cell renal cell carcinoma after surgery, positioning the regimen as a new postoperative option for eligible adults. The approval covers patients with clear cell RCC who have undergone resection of all or part of the kidney, reflecting continued expansion of immune checkpoint and hypoxia-pathway targeting. Pembrolizumab (an anti–PD-1 checkpoint inhibitor) plus belzutifan (a HIF-2α inhibitor) combines immune activation with suppression of a tumor oxygen-sensing axis. The decision adds a clinically differentiated option to the adjuvant landscape, where benefits depend heavily on patient risk profiles and tolerability. Clinicians and developers will now focus on uptake considerations—particularly sequencing and adverse-event management—while competitors recalibrate adjuvant trial strategies against checkpoint-based regimens.
-
Oncology immunotherapy: first-in-field pivotal-stage CAR T for liver cancer
Oricell Therapeutics has advanced its GPC3-targeted autologous CAR T therapy, Ori-C101, into a confirmatory registration-directed Phase 2 trial for patients with GPC3-positive advanced hepatocellular carcinoma. The company positions Ori-C101 as the first CAR T program for liver cancer to reach this stage, targeting a challenging solid-tumor immune cell niche. The move comes as CAR T developers seek clearer translational pathways from early efficacy to registration-grade confirmation in solid tumors. Oricell’s selection of a confirmatory Phase 2 framework suggests an endpoint strategy aimed at supporting a regulatory package. If Ori-C101 sustains response rates and durability in this pivotal-like setting, it could reshape how GPC3 is approached in cell therapy manufacturing and trial design for hepatocellular carcinoma.
-
Rare disease regulation and litigation: Amgen challenges FDA’s Tavneos withdrawal push
Amgen is contesting FDA concerns over Tavneos (avacopan), arguing for an independent review as the agency faces pressure to revisit whether the rare vasculitis drug should remain on the market. The FDA’s position is reported to be tied to safety risks and allegations surrounding clinical trial data and processes linked to securities fraud litigation involving ChemoCentryx, the original developer. The dispute puts Tavneos at the center of an FDA decision dynamic where evidentiary integrity and post-approval risk-benefit assessments collide. For Amgen, the review request is a direct attempt to preserve access while clarifying what the agency will rely on. Biopharma watchers will monitor how this case balances regulatory authority with disputes originating from corporate and litigation contexts—especially for other marketed drugs with contested data histories.
-
Biopharma financing: SonoThera raises $125M for ultrasound-mediated genetic medicines
SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines into clinical development, with the company targeting Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. The round was led by Vida Ventures and included major biotech and pharma investors. The company plans to use the financing to progress lead programs and expand its pipeline of targeted redosable genetic medicines. SonoThera’s platform combines an ultrasound-mediated delivery system (RIPPLE) with a payload engineering layer (PORE), aiming to address classic hurdles in gene therapy including delivery, immune responses, and redosing. SonoThera expects its first DMD clinical trial to begin in 2027, giving the market a clearer development cadence for non-viral, ultrasound-assisted delivery approaches.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.